Tsai Ming-Yen, Hu Wen-Long, Chiang Jen-Huai, Huang Yu-Chuen, Chen Shih-Yu, Hung Yu-Chiang, Chen Yung-Hsiang
Graduate Institute of Integrated Medicine, College of Chinese Medicine, Research Center for Chinese Medicine & Acupuncture, China Medical University, Taichung, Taiwan.
Department of Chinese Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan.
Oncotarget. 2017 Aug 8;8(52):90465-90476. doi: 10.18632/oncotarget.20063. eCollection 2017 Oct 27.
No previous studies have evaluated the effects of traditional Chinese medicine (TCM) treatment on patients with heart failure (HF). Hence, in this study, we determined whether TCM treatment affects the healthcare burden and survival of HF patients.
Samples were retrieved from the registry of catastrophic illness patients of the Taiwan National Health Insurance Research Database (NHIRD). Based on a frequency (1:1) matched case-control design, patients with HF between 2000 and 2010 were designated as cases (TCM users) and controls (non-TCM users). TCM treatment for patients with HF was analyzed.
Among these patients, 312 used TCM for HF treatment and exhibited significantly increased 5-year survival ( < .0001), with multivariate adjustment, compared with those without TCM use. Mean outpatient clinic visits at 1 year and 5 years after HF diagnosis were higher in TCM users, and accumulated medical costs were lower than in non-TCM users at 1 year. The hospitalization cost at 1-year follow-up was lower for TCM users than for non-TCM users. We found that, compared with non-TCM users, TCM users had an 86% reduction in risk of mortality in the compensated group, and a 68% reduction in the decompensated group receiving TCM treatment (aHR 0.32, 95% CI 0.20-0.52). The hazard ratio (HR) of Chinese herbal medicine (CHM) users with HF was significantly lower than that of non-users (aHR 0.24, 95% CI 0.16-0.35). We also analyzed the most commonly used herbal products as well as the HRs associated with their use, thus providing future research avenues.
This nationwide retrospective cohort study finds that combined therapy with TCM may improve survival in HF patients. This study also suggests that TCM may be used as an integral element of HF interventions on health care costs.
既往尚无研究评估中医治疗对心力衰竭(HF)患者的影响。因此,在本研究中,我们确定中医治疗是否会影响HF患者的医疗负担和生存率。
样本取自台湾国民健康保险研究数据库(NHIRD)的重大疾病患者登记处。基于频率(1:1)匹配的病例对照设计,将2000年至2010年间的HF患者指定为病例组(使用中医治疗者)和对照组(未使用中医治疗者)。对HF患者的中医治疗情况进行了分析。
在这些患者中,312例使用中医治疗HF,与未使用中医治疗的患者相比,经多变量调整后,其5年生存率显著提高(P<0.0001)。HF诊断后1年和5年时,使用中医治疗的患者平均门诊就诊次数更多,且1年时累积医疗费用低于未使用中医治疗的患者。中医治疗组1年随访时的住院费用低于未使用中医治疗组。我们发现,与未使用中医治疗的患者相比,中医治疗组在代偿组中的死亡风险降低了86%,在失代偿组中接受中医治疗的患者死亡风险降低了68%(校正风险比[aHR]为0.32,95%置信区间[CI]为0.20-0.52)。使用中药(CHM)的HF患者的风险比(HR)显著低于未使用者(aHR为0.24,95%CI为0.16-0.35)。我们还分析了最常用的草药产品及其使用相关的HR,从而为未来的研究提供了方向。
这项全国性回顾性队列研究发现,中医联合治疗可能会提高HF患者的生存率。本研究还表明,中医可作为HF干预措施中控制医疗费用的一个重要组成部分。